<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We treated 23 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>); 2 <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) with prior therapy, 11 RA with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), and 10 RAEB in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>), with daily oral 45 mg/m2 <z:hpo ids='HP_0000001'>all</z:hpo>-trans <z:chebi fb="2" ids="26536">retinoic acid</z:chebi> (ATRA) in a multiinstitutional prospective study </plain></SENT>
<SENT sid="1" pm="."><plain>In two patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and one with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>, a more than 1,000/microL increase of peripheral neutrophil counts was observed with some reduction of blast percentage in the bone marrow 2 to 9 weeks after the start of ATRA </plain></SENT>
<SENT sid="2" pm="."><plain>However, the effect was transient and did not last for more than 5 weeks despite the continuation of ATRA therapy </plain></SENT>
<SENT sid="3" pm="."><plain>In one other patient with RA, one patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, and one patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>, slight increase of <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> levels or reduction of blast percentage in bone marrow was noted </plain></SENT>
<SENT sid="4" pm="."><plain>Toxicities attributable to ATRA were minimal and included <z:hpo ids='HP_0100825'>cheilitis</z:hpo>, <z:hpo ids='HP_0000958'>xerosis</z:hpo>, <z:hpo ids='HP_0000964'>dermatitis</z:hpo>, <z:e sem="disease" ids="C0017178" disease_type="Disease or Syndrome" abbrv="">gastrointestinal disorders</z:e>, <z:hpo ids='HP_0002910'>abnormal liver function tests</z:hpo>, and high serum triglyceridemia </plain></SENT>
<SENT sid="5" pm="."><plain>Although ATRA works remarkably as a differentiation therapy in <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo>, its effect in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> included in this study was modest </plain></SENT>
<SENT sid="6" pm="."><plain>Further study of this agent alone or in combination may be warranted in less advanced stages of this disease </plain></SENT>
</text></document>